ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Associations of Leukocyte-Derived Chemotaxin-2 (LECT2) with Insulin Resistance and Metabolic Syndrome in Type 2 Diabetes: A Cross-Sectional Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Key Hepatokines Linking MASLD and Type 2 Diabetes: From Pathophysiological Mechanisms to Therapeutic Modulation.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Leukocyte-derived chemokine-2 (LECT2) is a novel neutrophil chemokine synthesized by the liver. This research aimed to investigate the potential link between LECT2 levels and metabolic syndrome (MetS) as well as insulin resistance (IR) in patients with type 2 diabetes mellitus (T2D). The results could offer fresh perspectives on the diagnosis and therapeutic strategies for T2D and associated metabolic disorders. Methods: A cross-sectional study was conducted on 148 T2D patients, including 90 with MetS and 58 without MetS. The diagnosis of MetS was based on the standardized guidelines established by the International Diabetes Federation. IR was assessed via HOMA-IR, with a cutoff of ≥2.69. Serum LECT2 levels were measured using ELISA. Results: In T2D patients, individuals with MetS exhibited significantly higher LECT2 levels than the non-MetS group (1.73±0.31 ng/mL vs 1.55±0.33 ng/mL, Conclusion: LECT2 concentrations were elevated in T2D patients combined with MetS and were significantly related to IR. These results indicate that LECT2 could contribute to the pathogenesis of T2D accompanied by MetS, and LECT2 may represent a promising therapeutic target for MetS and its related metabolic disturbances.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.